Last $55.24 USD
Change Today -1.05 / -1.87%
Volume 3.5M
MYL On Other Exchanges
As of 5:20 PM 01/28/15 All times are local (Market data is delayed by at least 15 minutes).

mylan inc (MYL) Snapshot

Previous Close
Day High
Day Low
52 Week High
11/28/14 - $59.60
52 Week Low
02/5/14 - $42.43
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for MYLAN INC (MYL)

mylan inc (MYL) Details

Mylan Inc., a pharmaceutical company, develops, licenses, manufactures, markets, and distributes generic, branded generic, and specialty pharmaceuticals worldwide. It operates in two segments, Generics and Specialty. The Generics segment primarily provides generic or branded generic pharmaceutical products in tablet, capsule, injectable, or transdermal patch form, as well as active pharmaceutical ingredients (APIs). This segment is also involved in developing APIs with non-infringing processes to partner with manufacturers; and the manufacture and sale of injectable products in the therapeutic areas of antineoplastics, anti-infectives, anesthesia/pain management, and cardiovascular. In addition, it produces finished dosage form (FDF) products for the antiretroviral (ARV) market and non-ARV FDF products that are marketed to third parties. This segment serves proprietary and ethical pharmaceutical wholesalers and distributors, group purchasing organizations, drug store chains, independent pharmacies, drug manufacturers, institutions, and public and governmental agencies. The Specialty segment manufactures and sells branded specialty injectable and nebulized products comprising EpiPen Auto-Injector for the treatment of severe allergic reactions; and Perforomist Inhalation Solution, a formoterol fumarate inhalation solution for the maintenance treatment of bronchoconstriction in chronic obstructive pulmonary disorder patients. It also offers ULTIVA, an analgesic agent used during the induction and maintenance of general anesthesia. This segment serves pharmaceutical wholesalers and distributors, pharmacies, and healthcare institutions. Mylan Inc. has a strategic collaboration with Pfizer Japan Inc. to develop, manufacture, distribute and market generic drugs in Japan. The company was formerly known as Mylan Laboratories Inc. and changed its name to Mylan Inc. in October 2007. Mylan Inc. was founded in 1961 and is headquartered in Canonsburg, Pennsylvania.

20,000 Employees
Last Reported Date: 02/27/14
Founded in 1961

mylan inc (MYL) Top Compensated Officers

Chief Executive Officer, Director and Member ...
Total Annual Compensation: $1.1M
President, Director and Member of Science & T...
Total Annual Compensation: $840.4K
Executive Chairman and Chairman of Executive ...
Total Annual Compensation: $1.4M
Chief Financial Officer and Executive Vice Pr...
Total Annual Compensation: $650.0K
Compensation as of Fiscal Year 2013.

mylan inc (MYL) Key Developments

Mylan Inc. Loses Patent Fight over MS Drug

The Supreme Court ruled against Mylan Inc. and other firms in their challenge of Teva Pharmaceutical Industries' patents for a blockbuster multiple sclerosis drug. The justices ruled 7-2 that a federal appeals court wrongly overturned five of Teva's patents for the drug Copaxone, which generates about $4 billion in annual sales for Teva. The majority told a lower court to reconsider a ruling invalidating the patents. The decision allows the Israel-based company to keep its exclusive rights to Copaxone until September, delaying generic competition from Mylan and the other companies. And it gives Teva more time to shift patients to a longer acting version that won't face competition until 2030. Teva had argued that the U.S. Court of Appeals for the Federal Circuit should not have second-guessed factual findings made by a federal district court that had ruled in Teva's favor. The Supreme Court agreed that the Federal Circuit should have deferred to factual findings made by the lower court. The other companies involved in the case are Momenta Pharmaceuticals Inc. and Sandoz Inc.

Mylan Reportedly In Talks With Famy Care

Mylan, Inc. (NasdaqGS:MYL) is in advanced discussions to acquire Famy Care Ltd. from JP Taparia family in a deal estimated at over $500 million, The Times of India reported citing people familiar with the matter. JP Taparia family had appointed Credit Suisse AG to explore strategic options for Famy Care Ltd. Bain Capital, LLC and Advent International Corporation were also the potential suitors. An emailed query to Mylan, Inc.'s spokesperson Nina Devlin remained unanswered at the time of going to press. An external spokesperson for Famy Care Ltd. said that the company has retained Credit Suisse AG but nothing has been finalized yet. And any talk about a deal currently is in the realm of speculation.

Mylan Inc. Launches Generic Version of Hepatitis B Virus Infection Drug in U.S

Mylan Inc. announced the U.S. launch of its Lamivudine tablets, 100 mg, which are indicated to treat chronic hepatitis B virus infection associated with evidence of hepatitis B viral replication and active liver inflammation. Lamivudine tablets are the generic version of GlaxoSmithKline's (GSK) Epivir-HBV.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
MYL:US $55.24 USD -1.05

MYL Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Omnicare Inc $75.50 USD -0.65
Perrigo Co PLC $153.51 USD -2.50
UCB SA €70.21 EUR +0.20
WW Grainger Inc $231.04 USD -0.64
WESCO International Inc $66.53 USD -0.34
View Industry Companies

Industry Analysis


Industry Average

Valuation MYL Industry Range
Price/Earnings 24.3x
Price/Sales 2.8x
Price/Book 6.2x
Price/Cash Flow 22.9x
TEV/Sales 1.7x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact MYLAN INC, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at